



### Company Overview

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.

### Emmaus Life Sciences Reports Quarterly Financial Results

Nov 14 2025, 3:57 PM EST

### Emmaus Life Sciences Reports Quarterly Financial Results

Aug 14 2025, 3:13 PM EDT

### Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements

Jun 26 2025, 9:30 AM EDT

### Stock Overview

|               |                 |
|---------------|-----------------|
| Symbol        | EMMA            |
| Exchange      | OTCQB           |
| Market Cap    | 824.19k         |
| Last Price    | \$0.01          |
| 52-Week Range | \$0.00 - \$0.04 |

11/14/2025 08:38 PM EST

### Management Team

#### Willis C. Lee, MS

Chief Executive Officer, Director

#### Charles W. Stark, Pharm.D.

Senior Vice President of Medical Affairs, Clinical, Regulatory

#### Dale E. Short, JD

Legal Consultant and Corporate Secretary

#### Hiroko Huynh

Chief Accounting Officer

### Emmaus Life Sciences, Inc.

21250 Hawthorne Blvd.  
Suite 800  
Torrance, CA 90503

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.